scispace - formally typeset
D

Donald E. Low

Researcher at University of Toronto

Publications -  362
Citations -  25624

Donald E. Low is an academic researcher from University of Toronto. The author has contributed to research in topics: Population & Streptococcus pneumoniae. The author has an hindex of 88, co-authored 359 publications receiving 24384 citations. Previous affiliations of Donald E. Low include Trillium Health Centre & New York City Department of Health and Mental Hygiene.

Papers
More filters
Journal ArticleDOI

The Legionella pneumophila Collagen-Like Protein Mediates Sedimentation, Autoaggregation, and Pathogen-Phagocyte Interactions

TL;DR: Overall, this study shows that L. pneumophila is capable of autoaggregating in a process that is mediated by Lcl in a divalent-cation-dependent manner, and reveals that Lcl potentiates the ability of L.neumophila to come in contact, attach, and infect amoebae.
Journal ArticleDOI

Evaluation of Susceptibility Testing To Detect Fluoroquinolone Resistance Mechanisms in Streptococcus pneumoniae

TL;DR: Isolates with only a parC mutation could not be detected reliably using any susceptibility testing method, and only isolates with both parC andgyrA mutations or with no recognized resistance mechanisms were reliably identified by using these results.
Journal ArticleDOI

Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005.

TL;DR: It is concluded that increasing macrolide resistance among respiratory isolates of pneumococci in Canada from 1995 to 2005 was associated both with decreasing prescriptions for erythromycin and concurrent increases in prescriptions for azithromyzin and clarithromycin by univariate and multivariate regression analyses.
Journal ArticleDOI

Optimization of microculture and evaluation of miniculture for the isolation of Leishmania parasites from cutaneous lesions in Peru.

TL;DR: Microculture and miniculture are sensitive and efficient means of diagnosing cutaneous leishmaniasis and are based on reference criteria for CL.
Journal ArticleDOI

A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus.

TL;DR: Quinupristin/dalfopristin, a semisynthetic derivative of pristinamycin, exhibits good in-vitro activity against methicillin-sensitive S. aureus and MRSA, and generally has a more rapid bactericidal action than vancomycin and oxacillin against many strains of MRSA.